A research team investigating a therapy for a difficult-to-treat cancer turned to ImmPro after conventional proteomics failed to validate the drug’s mechanism of action. Using the ProteoSight™ platform, ImmPro performed intact proteoform analysis that confirmed the intended target engagement, and revealed a previously undetected proteoform linked to therapeutic response. This newly identified species provided insight into potential patient stratification biomarkers and safety risks. The case study illustrates how top-down proteomics delivers the clarity needed to make confident development decisions—and exposes insights peptide-based methods can miss.

Download the full Case Study to see how ProteoSight™ delivers resolution.

*Access requires name, instituion, and email